Interleukin-2 not checked
Corregene Biotechnology Co., Ltd
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.”In the company’s words, NCT05122221 on ClinicalTrials.gov
- Tested for
- Cervical Cancer, Anal Cancer, Head and Neck Cancers
- Main trialPhase 1
- “A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D.”In the company’s words, NCT05122221 on ClinicalTrials.gov
Other drugs for Cervical Cancer
- SocazolimabLee's Pharmaceutical Limited · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- JSKN033Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase 3
- Bulumtatug fuvedotinMabwell · Phase 3
- SHR-A2102Hengrui · Phase 3
- SYS6002CSPC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | Mar 2023 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026